Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40

Mirtti Tuomas; Aittokallio Tero

首页> 外文期刊>European urology >Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40

【24h】

Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40

机译：Re：Fatemeh Seyednasrollah，Mehrad Mahmoudian，Liisa Rautakorpi，等。现实世界患者的抗性阉割前列腺癌患者中的基于试验的预后模型有多可靠？ EUR UROL。 2017; 71：838-40

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2017年第3期|共2页
作者
Mirtti Tuomas; Aittokallio Tero;
展开▼
作者单位

Univ Helsinki Inst Mol Med Finland Helsinki Finland;

Univ Helsinki Inst Mol Med Finland Helsinki Finland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40 [J] . Mirtti Tuomas, Aittokallio Tero European urology . 2017,第3期

机译：Re：Fatemeh Seyednasrollah，Mehrad Mahmoudian，Liisa Rautakorpi，等。现实世界患者的抗性阉割前列腺癌患者中的基于试验的预后模型有多可靠？ EUR UROL。 2017; 71：838-40
2. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? [J] . Seyednasrollah Fatemeh, Mahmoudian Mehrad, Rautakorpi Liisa, European urology . 2017,第5期

机译：现实世界患者的抗性阉割前列腺癌患者中的基于试验的预后模型有多可靠？
3. Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients [J] . Fizazi Karim, De Porre Peter, Londhe Anil, European urology . 2016,第2期

机译：回复Giandomenico Roviello，Alberto Bottini和Daniele Generali给编辑的信，关于：Karim Fizazi，Kim N. Chi，Johann S. de Bono等。转移性去势抵抗性前列腺癌患者长期服用低剂量泼尼松和醋酸阿比特龙后，皮质类固醇相关不良事件发生率低。 Eur Urol。在新闻。 http://dx.doi.org/10.1016/j.eururo.2016.02.035。老年患者皮质类固醇相关不良事件
4. A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate [O] . Daniel Joseph Khalaf, Claudia M. Avilés, Arun A. Azad, 2018

机译：醋酸阿比特龙治疗的单纯化疗转移性去势抵抗性前列腺癌患者临床预后分层的预后模型
5. Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8–10 Prostate Cancer. Eur Urol 2017;71:907–12 [O] . Christian Daniel Fankhauser, Lorelei A. Mucci, Travis A. Gerke 2017

机译：Re：Won sik Ham，Heather J. Chalfin，Zhaoyong Feng，et al。新的前列腺癌分级系统预测Gleason评分8-10前列腺癌手术后的长期生存率。 Eur Urol。在媒体上。 http://dx.doi.org/10.1016/j.eururo.2016.11.006

Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40

著录项

相似文献

相关主题

期刊订阅